Avidity Biosciences
10975 N. Torrey Pines Road
Suite 150
La Jolla
California
92037
United States
Tel: 858-401-7900
Website: http://www.aviditybiosciences.com/
Email: info@aviditybio.com
About Avidity Biosciences
Our vision is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics. We’re utilizing our proprietary AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) with the precision of oligonucleotide-based therapies in order to redefine RNA therapeutics and more effectively target underlying genetic drivers of diseases. We are delivering on this vision by investing in our platform, our pipeline and our people.
Our commitment to rigorous and innovative science is matched only by our passion to see patients’ lives changed. We consistently challenge ourselves to Be AVID – Agile, Visionary, Integrated and Diverse.
We are assembling a diverse team experienced in rare disease and RNA therapies. Our team members bring expertise in research, development and commercial execution. We are focused on cultivating the right team to not only grow the company, but also to reflect the communities we serve. We are dedicated to employing and retaining a diverse and inclusive workforce at all levels of the organization to not only ensure that different backgrounds and perspectives are being heard and acted upon, but that our employees also feel understood, accepted and valued.
75 articles with Avidity Biosciences
-
Avidity Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights
11/8/2022
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress.
-
Avidity Biosciences to Participate in Upcoming November 2022 Investor Conferences
11/1/2022
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the Avidity management team will be participating at the following upcoming conferences:
-
Avidity Biosciences Announces Phase 1/2 EXPLORE44™ Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping
10/11/2022
Avidity Biosciences, Inc. (Nasdaq: RNA) today announced the Phase 1/2 EXPLORE44™ clinical trial of AOC 1044 in healthy volunteers and participants with Duchenne muscular dystrophy (DMD), a rare, genetic condition that is characterized by progressive muscle damage and weakness.
-
Avidity Biosciences Announces Upcoming Presentations at 27th International Hybrid Annual Congress of World Muscle Society
10/6/2022
Avidity Biosciences, Inc. (Nasdaq: RNA) today announced the company will be presenting five poster presentations including the MARINA™ study design for myotonic dystrophy type 1 and preclinical and real-world data from the facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy (DMD) programs.
-
Avidity Biosciences Announces the Phase 1/2 FORTITUDE™ Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy
9/29/2022
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the Phase 1/2 FORTITUDE™ clinical trial of AOC 1020 in adults with facioscapulohumeral muscular dystrophy (FSHD).
-
The FDA ordered Avidity Biosciences to halt clinical trial enrollment after a patient suffered a "serious adverse event" testing the company's candidate drug for myotonic dystrophy type 1.
-
Avidity Biosciences Engages with Patient Communities During National Muscular Dystrophy Awareness Month as part of Commitment to Developing Muscular Dystrophy Programs
9/7/2022
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, honors National Muscular Dystrophy Awareness Month, an annual observance that raises awareness for families across the nation who are living with neuromuscular diseases.
-
Avidity Biosciences to Participate in Upcoming September 2022 Investor Conferences
9/1/2022
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the Avidity management team will be participating at the following upcoming conferences.
-
Avidity Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
8/9/2022
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced financial results for the second quarter ended June 30, 2022 and highlighted recent corporate progress.
-
Avidity Biosciences Enrolls Patients in the MARINA™ Open-Label Extension Study
8/2/2022
Avidity Biosciences, Inc. today announced that it has commenced enrolling patients from the Phase 1/2 MARINA™ study into a Phase 2 open-label extension study (MARINA-OLE™) of AOC 1001 in adults with myotonic dystrophy type 1 (DM1).
-
Avidity Biosciences Supports World Facioscapulohumeral Muscular Dystrophy (FSHD) Day and Presents Preclinical Data from FSHD Program
6/17/2022
Oral Presentation at FSHD IRC highlights preclinical data that demonstrated prevention of muscle weakness by reducing DUX4 expression.
-
Avidity Biosciences Announces Upcoming Presentations at the 29th Annual FSHD Society International Research Congress
6/9/2022
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced they will be presenting an oral and poster presentation at the 29th Annual FSHD Society International Research Congress in Orlando, Florida, June 16-17, 2022.
-
Avidity Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
5/10/2022
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced financial results for the first quarter ended March 31, 2022 and highlighted recent corporate progress.
-
Avidity Biosciences Expands Role of Michael MacLean to Chief Financial and Chief Business Officer
4/5/2022
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Michael MacLean, currently the chief financial officer, has expanded his role to include responsibilities as chief business officer.
-
Avidity Biosciences Announces Upcoming Presentations at the American Academy of Neurology 2022 Annual Meeting
3/29/2022
Avidity Biosciences, Inc. today announced they will be presenting at the American Academy of Neurology 2022 Annual Meeting in Seattle, Washington , April 2-7, 2022.
-
Avidity Biosciences Announces Upcoming Presentations at the 2022 MDA Clinical & Scientific Conference
3/7/2022
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced they will be presenting an oral presentation and multiple poster presentations at the 2022 MDA Clinical & Scientific Conference.
-
Avidity Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Highlights
3/1/2022
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2021 and highlighted recent corporate progress.
-
Avidity Biosciences Appoints Steve Hughes, M.D., as Chief Medical Officer
2/23/2022
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Steve Hughes, M.D. as chief medical officer.
-
Five Top CEOs to Watch in 2022
2/23/2022
Several CEOs have stood out from their peers throughout the past year, winning recognition from the Healthcare Technology Report. BioSpace looks at five of these leaders. -
Avidity Biosciences to Participate in Upcoming Investor Conferences - Feb 11, 2022
2/11/2022
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the Avidity management team will be participating at the following conferences.